| Literature DB >> 29044416 |
Qinwen Mao1, Dongyang Wang1, Yanqing Li1, Missia Kohler1, Jayson Wilson1, Zachary Parton1, Bella Shmaltsuyeva1, Demirkan Gursel1, Rosa Rademakers1, Sandra Weintraub1, Marek-Marsel Mesulam1, Haibin Xia1, Eileen H Bigio.
Abstract
Heterozygous loss-of-function mutations in GRN, the progranulin gene, which result in progranulin (PGRN) protein haploinsufficiency, are a major cause of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP). PGRN is composed of seven and a half repeats of a highly conserved granulin motif that is cleaved to produce the granulin peptides A-G and paragranulin. To better understand the role of PGRN and granulin (Grn) peptides in the pathogenesis of neurodegeneration, we evaluated PGRN/Grn in brains of patients with Alzheimer disease, FTLD-TDP type A with or without GRN mutations, and normal individuals, using a panel of monoclonal antibodies against Grn peptides A-G. In the neocortex, Grn peptide-specific immunostains were observed, for example, membranous Grn E immunopositivity in pyramidal neurons, and Grn C immunopositivity in ramified microglia. In the hippocampus, Grn immunopositivity in the CA1 and CA2 regions showed disease-specific changes in both neurons and microglia. Most interestingly, in FTLD-TDP type A with GRN mutations, there is a 60% decrease in the density of Grn-positive microglia in the hippocampal CA1, suggesting that haploinsufficiency of the GRN mutations also extends to PGRN expression in microglia. This study provides important insights into future studies of the pathogenesis and treatment of FTLD-TDP.Entities:
Keywords: Alzheimer disease; Frontotemporal lobar degeneration; Granulin; Hippocampal sclerosis; Microglia; Neuroinflammation; Progranulin
Mesh:
Substances:
Year: 2017 PMID: 29044416 PMCID: PMC5939662 DOI: 10.1093/jnen/nlx085
Source DB: PubMed Journal: J Neuropathol Exp Neurol ISSN: 0022-3069 Impact factor: 3.685